C07C59/76

Synthesis of alkyl 2-acetyl-5,9,13-trimethyltetradeca-4,8,12-trienoates and derivatives by a non-continuous production process
11274071 · 2022-03-15 · ·

The present invention relates to the manufacturing of a process of alkyl 2-acetyl-5,9,13-trimethyltetradeca-4,8,12-trienoates and alkyl 2-acetyl-9,13-di-methyl-5-methylenetetradeca-8,12-dienoate as well as 6,10,14-trimethylpenta-deca-5,9,13-trien-2-one and 10,14-dimethyl-6-methylenepentadeca-9,13-dien-2-5 one and 6,10,14-trimethylpentadecan-2-one.

PRODUCTION METHOD FOR RARE FATTY ACID USING NOVEL ENZYME, AND NOVEL RARE FATTY ACID

A method for producing a hydroxylated fatty acid by a hydration reaction using a novel enzyme derived from the genus Clostridium in the soil and using fatty acid as a substrate is provided by the present invention. In addition, a novel rare fatty acid with utility value which is obtained by the production method is also provided.

Compositions Comprising Oxo-Derivatives of Fatty Acids and Methods of Making and Using Same
20210230094 · 2021-07-29 ·

The present disclosure provides 15-oxo-EPA and 15-oxo-DGLA, compositions comprising 15-oxo-EPA and/or 15-oxo-DGLA, and methods of treating and/or preventing fibrosis, skin disorders, inflammation, kidney disease or renal dysfunction in a subject in need thereof by administering 15-oxo-EPA and/or 15-oxo-DGLA.

Compositions Comprising Oxo-Derivatives of Fatty Acids and Methods of Making and Using Same
20210230094 · 2021-07-29 ·

The present disclosure provides 15-oxo-EPA and 15-oxo-DGLA, compositions comprising 15-oxo-EPA and/or 15-oxo-DGLA, and methods of treating and/or preventing fibrosis, skin disorders, inflammation, kidney disease or renal dysfunction in a subject in need thereof by administering 15-oxo-EPA and/or 15-oxo-DGLA.

SYNTHESIS OF ALKYL 2-ACETYL-5,9,13-TRIMETHYLTETRADECA-4,8,12-TRIENOATES AND DERIVATIVES BY A NON-CONTINUOUS PRODUCTION PROCESS
20200308090 · 2020-10-01 ·

The present invention relates to the manufacturing of a process of alkyl 2-acetyl-5,9,13-trimethyltetradeca-4,8,12-trienoates and alkyl 2-acetyl-9,13-di-methyl-5-methylenetetradeca-8,12-dienoate as well as 6,10,14-trimethylpenta-deca-5,9,13-trien-2-one and 10,14-dimethyl-6-methylenepentadeca-9,13-dien-2-5 one and 6,10,14-trimethylpentadecan-2-one.

SYNTHESIS OF ALKYL 2-ACETYL-5,9,13-TRIMETHYLTETRADECA-4,8,12-TRIENOATES AND DERIVATIVES BY A NON-CONTINUOUS PRODUCTION PROCESS
20200308090 · 2020-10-01 ·

The present invention relates to the manufacturing of a process of alkyl 2-acetyl-5,9,13-trimethyltetradeca-4,8,12-trienoates and alkyl 2-acetyl-9,13-di-methyl-5-methylenetetradeca-8,12-dienoate as well as 6,10,14-trimethylpenta-deca-5,9,13-trien-2-one and 10,14-dimethyl-6-methylenepentadeca-9,13-dien-2-5 one and 6,10,14-trimethylpentadecan-2-one.

SYNTHESIS OF ORGANIC ACIDS FROM ALPHA-KETO ACIDS
20200231527 · 2020-07-23 ·

Methods for syntheses of organic acids from -keto acids, including methods for syntheses of isotopically encriched organic acids from -keto acids are disclosed. The isotopically enriched organic acids are useful, for example, in metabolic flux analyses.

SYNTHESIS OF ORGANIC ACIDS FROM ALPHA-KETO ACIDS
20200231527 · 2020-07-23 ·

Methods for syntheses of organic acids from -keto acids, including methods for syntheses of isotopically encriched organic acids from -keto acids are disclosed. The isotopically enriched organic acids are useful, for example, in metabolic flux analyses.

Compositions comprising oxo-derivatives of fatty acids and methods of making and using same

The present disclosure provides 15-oxo-EPA and 15-oxo-DGLA, compositions comprising 15-oxo-EPA and/or 15-oxo-DGLA, and methods of treating and/or preventing fibrosis, skin disorders, inflammation, kidney disease or renal dysfunction in a subject in need thereof by administering 15-oxo-EPA and/or 15-oxo-DGLA.

Compositions comprising oxo-derivatives of fatty acids and methods of making and using same

The present disclosure provides 15-oxo-EPA and 15-oxo-DGLA, compositions comprising 15-oxo-EPA and/or 15-oxo-DGLA, and methods of treating and/or preventing fibrosis, skin disorders, inflammation, kidney disease or renal dysfunction in a subject in need thereof by administering 15-oxo-EPA and/or 15-oxo-DGLA.